Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate to severe postpartum anaemia in Nigerian women

niversity of Lagos0 个研究点目标入组 1,400 人开始时间: 2022年10月3日最近更新: 2024年8月26日

适应症

试验速览

暂无简介。

•1. Women aged between 15 and 49 years
•2. Between 6 and 48 hours after delivery
•3. Baseline (enrollment) moderate or severe anemia (Hb = 9.9g/dl), confirmed by Hemocue haemoglobinometer
•4. Able and willing to give written informed consent

•1. Having received a blood transfusion, for any indication, within the last 3 months
•2. Symptomatic anemia and a need for urgent correction
•3. Known haemoglobinopathy such as sickle cell disease, HbCC disease
•4. Clinically confirmed malabsorption syndrome
•5. Known hypersensitivity or contraindication to any form of iron treatment, study drug or any of its excipients
•6. Self-reported pre-existing maternal depression or other psychiatric illness and as evidenced by a YES response to any past history of psychiatry ward hospitalization, psychiatry medications, behavioral changes, or past consultation with psychiatry services
•7. Severe allergic conditions such as severe asthma, eczema or other atopic condition
•8. Known autoimmune conditions e.g., systemic lupus erythematosus, rheumatoid arthritis or known severe drug allergies.
•9. Planning to move or reside outside the research area

发起方

niversity of Lagos